Product Description
Mechanisms of Action: TNFS10B Agonist
Novel Mechanism: Yes
Modality: Antibody
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Daiichi Sankyo
Company Location:
Company Founding Year: 2005
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Triple Negative Breast Cancer|Hepatocellular Carcinoma|Pancreatic Cancer|Ovarian Cancer|Non-Small-Cell Lung Cancer|Colorectal Cancer|Adenocarcinoma
Phase 1: Oncology Unspecified|Lymphoma|Colorectal Cancer
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT01124630 |
CS1008-A-U105 | P1 |
Completed |
Colorectal Cancer |
2013-07-01 |
2024-11-27 |
Primary Endpoints|Treatments |
|
NCT01220999 |
LUD2010-002 | P1 |
Completed |
Colorectal Cancer |
2012-06-27 |
2024-02-16 |
Primary Endpoints |
|
JapicCTI-090892 |
JapicCTI-090892 | P1 |
Completed |
Oncology Unspecified |
2010-03-31 |
|||
NCT00320827 |
Without Leukemic Component | P1 |
Completed |
Lymphoma |
None |
2024-02-16 |
Primary Endpoints|Treatments |
|
NCT01307891 |
F101004001 (UAB1028) | P2 |
Completed |
Triple Negative Breast Cancer |
2016-06-01 |
2019-03-19 |
Treatments |
|
JapicCTI-101138 |
JapicCTI-101138 | P2 |
Completed |
Hepatocellular Carcinoma |
2013-07-31 |
|||
NCT00969033 |
CS1008-A-E203 | P2 |
Terminated |
Colorectal Cancer |
2011-12-01 |
2024-11-27 |
Primary Endpoints|Treatments |
|
NCT00945191 |
CS1008-A-U205 | P2 |
Completed |
Ovarian Cancer |
2011-08-23 |
2024-02-16 |
Primary Endpoints |
|
NCT00991796 |
CS1008-A-E202 | P2 |
Completed |
Non-Small-Cell Lung Cancer |
2011-07-01 |
2024-02-16 |
Primary Endpoints|Treatments |
|
2007-005675-34 |
2007-005675-34 | P2 |
Completed |
Adenocarcinoma|Colorectal Cancer |
2011-05-30 |
2022-03-12 |
Treatments |
|
NCT00521404 |
CS1008-A-U201 | P2 |
Completed |
Pancreatic Cancer |
2010-08-20 |
2024-02-16 |
Primary Endpoints|Treatments |